Michael Barbella, Managing Editor07.18.22
Owen Mumford has appointed Bal Johal as Research and Development director, effective July 4.
“We welcome Bal very warmly into our business,” said Jarl Severn, managing director at Owen Mumford. “She has the background, experience and drive to continue to accelerate the innovation and forward-thinking that will see us achieve ambitious growth and set us apart from the competition.”
Johal brings a wealth of experience in the pharmaceutical and medical device sector, covering a range of therapeutic areas and dosage forms, most recently working as vice president of product development, quality, regulatory, and medical at Circassia. Prior to that, she held roles within research and development at GlaxoSmithKline, Pfizer, and Mundipharma Research Ltd.
Research and development has always been at the heart of Owen Mumford’s unique offer and represents a major pillar in the company’s strategic direction and development. The appointment of Johal into this role will enhance the quality and strength of the company’s existing pipeline. It also secures a well-defined path to deliver new ambitions in innovation, sustainable product design, life-cycle analysis and increased positive impact on healthcare professional and patient experience.
"To join Owen Mumford at this time is very exciting. With a combination of progress already made and some very talented people within the organisation, I can see that we will be able to deliver a high standard of success and innovation that will have a truly positive impact,” Johal said.
Owen Mumford designs, manufactures, and advances medical technology, commercializing medical products in its own brand and custom device solutions for the world’s major pharmaceutical and diagnostic companies. It has pioneered the evolution of medical devices for nearly 70 years with solutions for the ease and comfort of administering life-saving medication, safe and comfortable blood sampling and testing, and rapid professional and self-diagnostic testing kits. The company has a global presence across the United Kingdom, United States, Europe, and Asia, and is a partner to many of the world’s biggest diagnostic and pharmaceutical companies.
“We welcome Bal very warmly into our business,” said Jarl Severn, managing director at Owen Mumford. “She has the background, experience and drive to continue to accelerate the innovation and forward-thinking that will see us achieve ambitious growth and set us apart from the competition.”
Johal brings a wealth of experience in the pharmaceutical and medical device sector, covering a range of therapeutic areas and dosage forms, most recently working as vice president of product development, quality, regulatory, and medical at Circassia. Prior to that, she held roles within research and development at GlaxoSmithKline, Pfizer, and Mundipharma Research Ltd.
Research and development has always been at the heart of Owen Mumford’s unique offer and represents a major pillar in the company’s strategic direction and development. The appointment of Johal into this role will enhance the quality and strength of the company’s existing pipeline. It also secures a well-defined path to deliver new ambitions in innovation, sustainable product design, life-cycle analysis and increased positive impact on healthcare professional and patient experience.
"To join Owen Mumford at this time is very exciting. With a combination of progress already made and some very talented people within the organisation, I can see that we will be able to deliver a high standard of success and innovation that will have a truly positive impact,” Johal said.
Owen Mumford designs, manufactures, and advances medical technology, commercializing medical products in its own brand and custom device solutions for the world’s major pharmaceutical and diagnostic companies. It has pioneered the evolution of medical devices for nearly 70 years with solutions for the ease and comfort of administering life-saving medication, safe and comfortable blood sampling and testing, and rapid professional and self-diagnostic testing kits. The company has a global presence across the United Kingdom, United States, Europe, and Asia, and is a partner to many of the world’s biggest diagnostic and pharmaceutical companies.